Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Deflazacort in Dermatitis, Atopic: CTRI/2026/01/100205 Clinical Landscape Report 2026
15 October 2026
CTRI/2026/01/100205 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetylcysteine in Dermatitis, Atopic: NCT07323719 Clinical Landscape Report 2026
15 October 2026
NCT07323719 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Ovarian Epithelial Carcinoma: CTRI/2026/01/100309 Clinical Landscape Report 2026
15 October 2026
CTRI/2026/01/100309 clinical landscape for Ovarian Epithelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Codeine Phosphate/Acetaminophen in Alzheimer Disease: NCT07323914 Clinical Landscape Report 2026
15 October 2026
NCT07323914 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Galcanezumab-gnlm in Alzheimer Disease: NCT07323927 Clinical Landscape Report 2026
15 October 2026
NCT07323927 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ocrelizumab Biosimilar(Biocad) in Multiple Sclerosis, Relapsing-Remitting: NCT07321093 Clinical Landscape Report 2026
15 October 2026
NCT07321093 clinical landscape for Multiple Sclerosis, Relapsing-Remitting: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Drotokibart in Moderate Atopic Dermatitis: NCT07321951 Clinical Landscape Report 2026
15 October 2026
NCT07321951 clinical landscape for Moderate Atopic Dermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JNJ-88545223 in Arthritis, Psoriatic: NCT07321873 Clinical Landscape Report 2026
15 October 2026
NCT07321873 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nomelcitinib in Plaque psoriasis: NCT07326813 Clinical Landscape Report 2026
15 October 2026
NCT07326813 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Ovarian Cancer: NCT07322094 Clinical Landscape Report 2026
15 October 2026
NCT07322094 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Frexalimab in Multiple Sclerosis: NCT07325292 Clinical Landscape Report 2026
15 October 2026
NCT07325292 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apremilast in Plaque psoriasis: NCT07337434 Clinical Landscape Report 2026
15 October 2026
NCT07337434 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.